Reliability of a novel approach for reference-based cell type estimation in human placental DNA methylation studies

Elisabeth Binder, Emory University
L Dieckmann, Max Planck Inst Psychiat
C Cruceanu, Max Planck Inst Psychiat
M Lahti-Pulkkinen, University of Helsinki
J Lahti, University of Helsinki
T Kvist, University of Helsinki
H Laivuori, University of Helsinki
S Sammallahti, University of Helsinki
PM Villa, Tampere University Hospital
S Suomalainen-Koenig, Helsinki University Central Hospital

Only first 10 authors above; see publication for full author list.

Journal Title: CELLULAR AND MOLECULAR LIFE SCIENCES
Volume: Volume 79, Number 2
Publisher: SPRINGER BASEL AG | 2022-02-01, Pages 115-115
Type of Work: Article
Publisher DOI: 10.1007/s00018-021-04091-3
Permanent URL: https://pid.emory.edu/ark:/25593/vvhkg

Final published version: http://dx.doi.org/10.1007/s00018-021-04091-3
Accessed December 2, 2022 4:11 PM EST
Reliability of a novel approach for reference-based cell type estimation in human placental DNA methylation studies

Linda Dieckmann1,2 · Cristiana Cruceanu1 · Marius Lahti-Pulkkinen3,4,5 · Jari Lahti3 · Tuomas Kvist3 · Hannele Laivuori6,7,8 · Sara Sammallahti9,10 · Pia M. Villa8,11,12 · Sanna Suomalainen-König11 · Rebecca C. Rancourt13 · Andreas Plagemann13 · Wolfgang Henrich14 · Johan G. Eriksson15,16,17,18 · Eero Kajantie4,9,19,20 · Sonja Entringer21,22 · Thorsten Braun14 · Katri Räikkönen3 · Elisabeth B. Binder1,23 · Darina Czamara1

Received: 25 August 2021 / Revised: 24 November 2021 / Accepted: 13 December 2021 / Published online: 3 February 2022 © The Author(s) 2022

Abstract
The placenta is a central organ during early development, influencing trajectories of health and disease. DNA methylation (DNAm) studies of human placenta improve our understanding of how its function relates to disease risk. However, DNAm studies can be biased by cell type heterogeneity, so it is essential to control for this in order to reduce confounding and increase precision. Computational cell type deconvolution approaches have proven to be very useful for this purpose. For human placenta, however, an assessment of the performance of these estimation methods is still lacking. Here, we examine the performance of a newly available reference-based cell type estimation approach and compare it to an often-used reference-free cell type estimation approach, namely RefFreeEWAS, in placental genome-wide DNAm samples taken at birth and from chorionic villus biopsies early in pregnancy using three independent studies comprising over 1000 samples. We found both reference-free and reference-based estimated cell type proportions to have predictive value for DNAm, however, reference-based cell type estimation outperformed reference-free estimation for the majority of data sets. Reference-based cell type estimations mirror previous histological knowledge on changes in cell type proportions through gestation. Further, CpGs whose variation in DNAm was largely explained by reference-based estimated cell type proportions were in the proximity of genes that are highly tissue-specific for placenta. This was not the case for reference-free estimated cell type proportions. We provide a list of these CpGs as a resource to help researchers to interpret results of existing studies and improve future DNAm studies of human placenta.

Keywords Cell type estimation · DNA methylation · Human placenta · Chorionic villi · Reference-based deconvolution · Reference-free deconvolution

Introduction
Since the Developmental Origins of Health and Disease (DOHaD) hypothesis was proposed, converging evidence supports the high importance of intrauterine conditions for development, as well as for health and disease outcomes later in life [1–3]. The placenta is a complex organ with a central role in fetal development and regulation of the intrauterine environment throughout pregnancy [4–6]. Thus, a better understanding of the placenta’s critical role for early development and its molecular landscape is key to disentangling some of the mechanisms driving DOHaD-related developmental aspects [7]. Epigenetic processes are essential for placental development and function, and correspondingly
healthy fetal development [8, 9]. Consequently, human studies of the placental epigenome are valuable and can help to increase our knowledge about trajectories of health and disease originating in early life.

DNA methylation (DNAm) is one of the most commonly studied epigenetic marks and it is known to be highly tissue- and cell-type-specific. Accordingly, it is important to distinguish direct (true) associations between the exposure of interest and DNAm from associations mediated through or otherwise caused by placental cell type distributions [10, 11].

To this end, cell type deconvolution algorithms have been developed to retrieve information about cell type composition from DNAm data. They can be mainly categorized into reference-based and reference-free methods [10]. Reference-based cell type deconvolution algorithms rely on biologically defined 5′-C-phosphate-G-3′ (CpG) sites that are uniquely methylated in purified cell types and were identified in a reference sample. For reference-free deconvolution, no a-priori knowledge about differential methylation from purified cell types is necessary, but cell types are predicted directly from DNAm using a computational approach [12]. The first reference-based method to infer changes in the distribution of white blood cells using DNAm signatures was proposed in 2012 by Houseman et al. [13], and pioneering algorithms for reference-free cell type deconvolution were published in 2014 [14, 15]. While reference-free methods are useful when no reference is available, reference-based methods are preferred if a reference is available and there is no evidence for other confounders [10, 16]. To date, the effectiveness of reference-free cell type deconvolution for placenta has not been assessed, and only recently a reference profile for placenta was published [17]. The establishment and validation of this reference in 28 samples constitutes important progress and now allows a reference-based cell type estimation in placenta.

However, an assessment of the performance of this reference-based versus reference-free cell type estimation in placenta with larger study samples is crucial for informing future research. In the current study, we demonstrate the impact of reference-based versus reference-free estimated cell types on DNAm in placental tissue and compare their informativeness. Further, we provide an overview of estimated cell types in placental samples from three independent studies, taken at birth \((n = 470, n = 139, n = 137)\) and, in the largest of these three studies, also during the first trimester \((n = 264)\). Our study contributes to a more detailed understanding of human placental characteristics regarding the relatedness of DNAm and cell type composition and underscores the importance of considering cell types in future DNAm studies using placental tissue.

### Materials and methods

#### Study populations

Placental tissue samples were collected from the InTraUterine sampling in early pregnancy (ITU) study, the Prediction and Prevention of Preeclampsia and Intraterine Growth Restriction (PREDO) study [18], and the Betamethasone (BET) study [19].

ITU and PREDO are Finnish cohort studies consisting of women and their children who were followed throughout pregnancy and beyond. In ITU, women were recruited through the national voluntary prenatal screening program for trisomy 21. If this screening indicated an increased risk of fetal chromosomal abnormalities based on routine serum, ultrasound screening, age and patient history, women were offered further testing including chorionic villus sampling (CVS) at the Helsinki and Uusimaa Hospital District Feto-maternal Medical Center (FMC). During this visit, women were informed about the ITU study. If the chromosomal test indicated no fetal chromosomal abnormality, those who had expressed interest in participating were contacted for final recruitment. Another set of women were informed about ITU when attending the routine screening at maternity clinics. If interest in participating was expressed, they were contacted for final recruitment into the ITU study. In PREDO, the recruitment took place when women attended their first routine ultrasound screening. Some of the women were recruited based on having clinical risk factors for preeclampsia and intrauterine growth restriction, others were recruited independently of these factors [18]. The aim of the BET study was to investigate the effect of antenatal betamethasone on the transplacental cortisol barrier and fetal growth [19]. Pregnant women with preterm labor and cervical shortening were treated with a single course of antenatal BET (Celestan®, MSD GmbH, Haar, Germany) for fetal maturation between 23 + 5 and 34 + 0 weeks of gestation and were recruited prospectively before birth. A gestational-age-matched control group consisted of pregnant women who received no antenatal BET.

#### Placental tissue samples

In the ITU study, first-trimester placental biopsies were obtained from leftover CVS, following indications of elevated risk for chromosomal abnormalities between 10 and 15 weeks of gestation. Placenta samples were also collected at birth, whereby midwives/trained staff took nine-site biopsies (within maximum 120 min after delivery) from the fetal side of the placenta, at 2–3 cm from umbilical cord insertion. In the PREDO study, placenta nine-site biopsies...
(within maximum 90 min after delivery) were taken from the decidual side of the placenta. In the BET study, full-thickness placental biopsies were taken by a uniform random sampling protocol [20, 21] from both peripheral and central areas. All samples were stored at −80 °C.

Throughout the manuscript, we refer to all placental samples collected at birth as ‘term placenta’, and to all placental CVS samples collected during early pregnancy as ‘CVS’.

**DNA methylation (DNAm)**

From the collected samples, DNA was extracted according to standard procedures and DNAm was assessed using the Illumina Infinium MethylationEPIC array (Illumina, San Diego, USA). In total, DNA methylation levels were assessed in 1055 samples: n = 277 CVS samples (ITU), and n = 500 placental samples (ITU), n = 140 placental samples (PREDO), and n = 138 placental samples (BET) taken at birth. All DNAm data were pre-processed in the same way, using an adapted pipeline from Maksimovic et al. [22] and the R package minfi [23]. Beta values were normalized using stratified quantile normalization [24], followed by BMIQ [25]. Batch-effects were removed using ComBat [26].

The final data sets comprised 264 CVS samples from ITU (n = 716,331 probes) and 486 placental samples (n = 665,190 probes) from ITU, 139 placenta samples (n = 755,154 probes) from PREDO and 137 placenta samples (n = 708,222 probes) from the BET study. Of these, 652,341 probes overlapped across all four data sets.

**Gestational age, child sex and ethnicity variables**

Gestational age (GA) at sampling was based on fetal ultrasound. Child sex was extracted from the Finnish Medical Birth Register (MBR) in ITU and PREDO and obtained from postnatal assessment in the BET study. To retrieve information about genetic background, we performed multi-dimensional scaling (MDS) analysis on the identity-by-state (IBS) matrix of quality-controlled genotypes [27]. We used the first two components for ITU and PREDO and the first four components for the BET study, as it was ethnically more heterogenous. In the following, we refer to these MDS components as ‘PC 1/2/3/4 ethnicity’, respectively. This information was available for n = 200 individuals with CVS tissue in ITU, and n = 439 individuals with term placental tissue in ITU, in n = 118 individuals with term placental tissue in PREDO and n = 136 individuals with term placental tissue in BET. Genotyping was performed on Illumina Infinium Global Screening arrays for BET and ITU and on Illumina Human Omni Express Arrays for PREDO. DNA for genotyping was extracted from cord blood in ITU and PREDO, if available, otherwise placental tissue was used in ITU. DNA was extracted from placental tissue in the BET study. Further details about genotypic assessment and quality control

| Table 1 Study sample characteristics [Mean (SD) or N (%) for each variable] |
|-------------------------------------------------|
| ITU                  | CVS (N=264) | Placenta (N=470) | PREDO (N=139) | BET (N=137) |
| Sample size       | 264         | 470             | 139           | 137         |
| Phenotypes        |             |                 |               |             |
| Gestational age   | 12.79 (0.82)| 39.99 (1.55)    | 39.89 (1.43)  | 38.16 (1.95) |
| Child sex (male)  | 140 (53%)   | 238 (51%)       | 67 (48%)      | 70 (51%)    |
| Reference-based cell types |
| Trophoblasts      | 0.26 (0.06) | 0.01 (0.03)     | 0.04 (0.05)   | 0.13 (0.06) |
| Stromal           | 0.17 (0.06) | 0.01 (0.02)     | 0.04 (0.03)   | 0.11 (0.02) |
| Hofbauer          | 0.00 (0.01) | 0.00 (0.01)     | 0.00 (0.00)   | 0.00 (0.00) |
| Endothelial       | 0.00 (0.01) | 0.01 (0.02)     | 0.08 (0.03)   | 0.11 (0.02) |
| nRBC              | 0.00 (0.01) | 0.04 (0.03)     | 0.00 (0.01)   | 0.00 (0.00) |
| Syncytiotrophoblasts | 0.57 (0.04) | 0.93 (0.06)    | 0.83 (0.08)   | 0.66 (0.08) |
| Reference-free cell types |
| C1                 | 0.26 (0.14) | 0.11 (0.09)     | 0.43 (0.19)   | 0.35 (0.2)  |
| C2                 | 0.30 (0.15) | 0.07 (0.07)     | 0.51 (0.20)   | 0.46 (0.2)  |
| C3                 | 0.14 (0.07) | 0.23 (0.13)     | –             | 0.14 (0.1)  |
| C4                 | 0.10 (0.07) | 0.13 (0.09)     | –             | –           |
| C5                 | 0.14 (0.10) | 0.13 (0.09)     | –             | –           |
| C6                 | –           | 0.11 (0.08)     | –             | –           |
| C7                 | –           | 0.09 (0.07)     | –             | –           |
| C8                 | –           | 0.08 (0.07)     | –             | –           |
in the ITU and PREDO cohorts, as well as in the BET study, have been published elsewhere [28, 29].

An overview of study sample characteristics is given in Table 1.

**Cell type composition estimation**

Reference-based cell type composition into six cell types (nucleated red blood cells, trophoblasts, syncytiotrophoblasts, stromal, Hofbauer, endothelial) was estimated using a reference recently published by Yuan et al. [17] and implemented within the R package *planet*, by applying the robust partial correlation algorithm [30].

The result of this cell type estimation is the amount of the respective cell types in every person, while all estimated cell types add up to 100%.

Reference-free cell types were estimated following the protocol suggested in the R package *RefFreeEWAS* [31], which led to five estimated ‘cell types’ in CVS (ITU), and eight estimated ‘cell types’ (ITU), two estimated ‘cell types’ (PREDO) and three estimated ‘cell types’ (BET) in term placenta. We refer to cell types here, although the output of this procedure does not give explicit cell types, but latent quantities and their respective proportion for every person.

**Statistical analyses**

All statistical analyses were performed in R, version 4.0.5/4.1.1 [32].

**Filtering of invariable probes in DNAm**

To assess the influence of cell types on DNAm, we first filtered for variable CpGs by excluding placenta-specific non-variable CpGs. We applied a procedure described by Edgar et al. [33] to the overlapping CpGs (n = 652,341) of all four placental methylation data sets from the EPIC array, to identify sites with < 5% range between 10 and 90th percentile in DNAm beta values using our data sets. This resulted in 120,548 CpGs (listed in Supplementary Table S1) that we identified as non-variable for placental EPIC methylation data and excluded from further analyses. Identifying these CpGs is useful to reduce dimensionality, and becomes especially relevant for future studies, e.g., epigenome-wide association studies (EWAS), aiming to use our resources. Furthermore, the 1050 CpGs used to predict cell type composition in the model by Yuan et al. [17] were excluded from the following analyses to prevent circular conclusions.

**Capturing DNAm variance through principal components and filtering of individuals**

To capture the major variance in DNAm, we performed singular value decomposition on methylation beta values, and extracted the first principal component (PC1) explaining most of the variance for every data set (Supplementary Fig. S1). For term placenta from ITU we identified n = 16 outliers representing values greater than three times interquartile-range in PC1 (see Supplementary Fig. S2a). The same samples showed lower sample-sample correlations in DNAm beta values with the other placenta samples (Supplementary Fig. S2b) and presented different cell type proportions (Supplementary Fig. S2c). Thus, we excluded these samples from the ITU placenta data set, resulting in n = 470 term placenta samples from the ITU cohort. We calculated the principal components (PC) without these outliers in the ITU term placenta data set. For CVS from ITU and term placenta data sets from PREDO and BET no such outliers were identified.

**Correlation of reference-free estimated cell types with reference-based estimated cell types and phenotypes**

Spearman’s rank correlations were calculated both between reference-free and reference-based estimated cell types and between reference-free estimated cell types and phenotypes (GA, child sex, ethnicity PCs and additionally fetal chromosomal testing and BET administration status in the ITU and BET placenta, respectively) in every tissue. Adjustment for multiple testing was done using Bonferroni correction.

**Models to predict DNAm by cell type proportions (reference-based versus reference-free)**

To compare the impact of reference-based versus reference-free estimated cell types on the main variance in DNAm, PC1 of DNAm beta values was regressed linearly on different predictors in six models for every data set:

1. PC methylation ~ 1
2. PC methylation ~ GA at sampling + child sex + PCs ethnicity
3. PC methylation ~ reference-based estimated cell types
4. PC methylation ~ reference-based estimated cell types + GA at sampling + child sex + PCs ethnicity
5. PC methylation ~ reference-free estimated cell types
6. PC methylation ~ reference-free estimated cell types + GA at sampling + child sex + PCs ethnicity

Using cross-validation with 10 folds, 500 repeats and RMSE as loss function, implemented in the R package
**Enrichment analyses**

All CpGs were mapped to the closest gene using the R package *bumphunter* functions *annotateTranscripts* and *matchGenes* [35]. Afterwards, the genes corresponding to the extracted CpGs were used as input for the *TissueEnrich* package [36], while the genes corresponding to all CpGs overlapping between the data sets (without any filtering for $R^2$) were considered as background genes ($n = 20,038$). The same input and background genes were further used for the *PlacentaCellEnrich* Tool [37]. Human placental single-cell RNA-Sequencing data [38] were used to retrieve enrichments for placenta cell-specific expression patterns. For both enrichment analyses we used an adjusted $p$ value of 0.01 as threshold for enrichment, as recommended by the authors of the *PlacentaCellEnrich* Tool [37].

**Cell type composition analyses**

Differences in reference-based cell type proportions between the three term placenta data sets were analyzed using non-parametric global multivariate analysis of variance [39] implemented in the R package *npmv* [40]. To test for significant differences between the study groups, we applied the global test using the $R$ function *nonpartest* with default settings, which provides $F$-distribution approximations, performs multivariate permutation and calculates nonparametric relative effects. The global test was supplemented with a more detailed comparison ($R$ function *ssnonpartest*) of study groups and cell types using the $F$ approximation of Wilks’ lambda, to identify which variables/factor levels contribute to the significant differences, while controlling for the familywise error rate ($\alpha = 0.01$).

Differences in reference-based cell type proportions between CVS and term placenta from the same individuals ($n = 85$, ITU) were calculated using paired Wilcoxon signed-rank tests. All $p$ values were corrected for multiple testing ($n = 6$ cell types) using Bonferroni correction and compared to $\alpha = 0.01$.

Spearman correlations and Wilcoxon signed-rank tests were performed to test for relationships between reference-based cell type proportions and GA and child sex (for every cell type separately and corrected for multiple testing among the $n = 6$ cell types using Bonferroni correction and $\alpha = 0.01$).

**Results**

**Reference-free estimated cell types do not map to reference-based estimated cell types and are correlated with child sex**

For an illustration of the correspondence between reference-based and reference-free estimated cell types, Spearman correlation coefficients are shown in Fig. 1. Although there were some correlations between reference-based and reference-free estimated cell types, there was no clear matching between reference-based estimated cell types and specific reference-free components. Furthermore, Spearman correlation coefficients for reference-free estimated cell types and included phenotypes are depicted in Fig. 2. It can be seen that especially child sex was correlated with the reference-free estimated cell type components.
Fig. 1 Plot of the Spearman correlation coefficients (**p < 0.001, *p < 0.01) between reference-based and reference free estimated cell types in a first trimester placenta (CVS) from ITU, b term placenta form ITU, c term placenta from PREDO and d term placenta from the BET study.

Fig. 2 Plot of the Spearman correlation coefficients (**p < 0.001, *p < 0.01) between reference free estimated cell types and phenotypes in a first trimester placenta (CVS) from ITU, b term placenta form ITU, c term placenta from PREDO and d term placenta from the BET study.
For the majority of data sets, reference-based methods predict variability of DNA methylation better than reference-free methods

To evaluate the impact of phenotypic variables (GA, child sex, ethnicity) vs. reference-based vs. reference-free cell type composition on the main variance in DNA methylation (DNAm) (PC1), we compared the predictive performance of six competing models: an intercept-only model (model 1), phenotype model (model 2), reference-based cell type model with or without phenotypes (model 3 and 4) and reference-free cell type model with or without phenotypes (model 5 and 6). All models were tested in each data set among individuals with complete information available (n = 200 for CVS from ITU, n = 425 for term placenta from ITU, n = 118 for term placenta from PREDO and n = 136 for term placenta from the BET study with five outliers excluded (see “Materials and methods”) resulting in n = 131).

The results of the cross-validation procedure for model selection are shown in Fig. 3. Models including cell type estimations always performed better than the intercept-only model (model 1) or a model including only phenotypes (GA, sex, ethnicity; model 2). In CVS data (Fig. 3a), the model including reference-based cell types only (model 3) gave the most accurate out-of-sample predictions of PC1 (80% of the wins), with an average prediction error of 79.58 (95% CI [78.57, 80.89]), followed by the model including reference-based cell types and phenotypes (model 4, for BET) or only reference-based cell types (model 3, for PREDO).

The conclusions from predicting DNA methylation variability in single CpGs by either reference-based or reference-free estimated cell types were concordant with the model for PC1 in DNAm. On average, reference-based cell types explained more variance (adjusted $R^2$) in DNAm compared to reference-free cell types among CpGs in CVS from ITU (n = 264; $R^2_{\text{Adjusted}} M = 0.13, SD = 0.17$ vs. $M = 0.12, SD = 0.12$), and in placental tissues at birth in PREDO (n = 139; $R^2_{\text{Adjusted}} M = 0.11, SD = 0.16$ vs. $M = 0.05, SD = 0.06$), and in BET (n = 137; $R^2_{\text{Adjusted}} M = 0.10, SD = 0.13$ vs. $M = 0.06, SD = 0.07$). Only placental tissues sampled at birth in ITU (n = 470), reference-free estimated cell types explained more of the variance in DNAm ($R^2_{\text{Adjusted}} M = 0.18, SD = 0.18$) than reference-based estimated cell types ($R^2_{\text{Adjusted}} M = 0.11, SD = 0.15$).

CpGs with larger proportions of variability explained by reference-based cell types map to placenta-specific genes

CpGs where estimated cell type composition explained more than 30% of variance (adjusted $R^2 > 0.3$) in all four data sets were considered as CpGs at which variability was relatively strongly influenced by cell type proportions. A list of these CpGs and corresponding genes can be found in Supplementary Table S2. For the reference-based model, this was the case for 26,092 CpGs mapping to 8511 genes. For the reference-free model, this was true for 531 CpGs mapping to 398 genes.

The results of the tissue enrichment analyses can be seen in Fig. 4. When using the reference-based estimated cell types, genes mapping to CpGs where variability was strongly influenced by cell types were enriched for placenta-specific genes (Fig. 4a, $p < 0.001$ and fold-change = 1.291). We provide a list of these 186 placenta-specific genes in Supplementary Table S3. For reference-free estimated cell types, genes mapping to CpGs where variability is strongly influenced by cell types were not enriched for placenta-specific genes (Fig. 4b): only 10 genes were found to be placenta-specific. However, there was an enrichment for cerebral cortex, with $p < 0.001$, fold-change = 2.209.

Next, we ran cell-specific enrichment analysis using a placenta-specific dataset (PlacentaCellEnrich Tool). Cell-specific expression patterns can be seen in Fig. 5. Again, the results reflect a higher placenta-specificity when using the reference-based approach (Fig. 5a), showing a significant enrichment for a number of placental cells as follows: syncytiotrophoblasts, villous cytotrophoblast, extravillous...
Fig. 3 Cross-validation results for predicting PC1 of DNAm comparing 6 models (model 1 = intercept-only; model 2 = phenotypes (gestational age (GA), child sex, ethnicity); model 3 = reference-based estimated cell types; model 4 = reference-based estimated cell types and phenotypes; model 5 = reference-free estimated cell types; model 6 = reference-free estimated cell types and phenotypes). The upper panel illustrates the proportions of wins among all repetitions for each model (models with zero wins overlap and hence not all colors are displayed), and the winning model is listed. The panel below shows the boxplots of the prediction error (root mean square error of prediction, RMSE_p) for all six models with the number of wins for each model displayed at the top. The panel on the right is a graph of density estimates for the prediction errors. Models were compared independently in four different tissue samples, a first trimester placenta (CVS) from ITU, b term placenta from ITU, c term placenta from PREDO and d term placenta from the BET study.
Fig. 4  Tissue enrichment among genes mapped to CpGs with a minimum of 30% explained variance in DNAm predicted by cell type proportions from a reference-based cell type estimation and b reference-free cell type estimation.
Fig. 5 Enrichment for placental cell-specific genes among genes mapped to CpGs with a minimum of 30% explained variance in DNAm predicted by cell type proportions from a reference-based cell type estimation and b reference-free cell type estimation.
trophoblast, fetal fibroblasts, stromal cells, endothelial cells and decidua perivascular cells. These represent the major cell types in the placenta [41], indicating that this approach accounted for the majority of confounding possible from cell type heterogeneity. Using the reference-free approach (Fig. 5b) there was only an enrichment of villous cytotrophoblasts. A summary of parameters of the cell-specific enrichment can be found in Supplementary Table S4.

**Cell type composition**

We next wanted to estimate the cell type proportions in the different study samples using the reference-based method (Fig. 6).

**Cell type proportions in term placentas show differences between studies**

While cell type estimates were highly similar for samples within a study, we observed significantly different estimated cell type proportions among the three studies with placental samples collected at birth, according to each of the four test criteria (ANOVA type, Lawley-Hotelling type, Bartlett–Nanda–Pillai type, and Wilks’ lambda type). Test statistics are given in Supplementary Table S5. Nonparametric relative effects, quantifying the probability that a value obtained from one study sample is larger than a value randomly chosen from the other study samples, are provided in Supplementary Table S6. The post-hoc testing procedure following the global test determined that samples from all three studies and all cell types contributed to these significant differences. In all three term placenta data sets, syncytiotrophoblasts were the main estimated cell type, but the highest proportion was estimated in term placenta from ITU. Estimates for proportions of trophoblasts, stromal and endothelial cells were highest in the BET study sample, followed by term placenta from PREDO.

**Cell type proportions show intra-individual changes from CVS to term Placenta**

The estimated cell type proportions differed significantly between early-pregnancy CVS and placenta sampled at birth for a number of cell types. Largest differences in estimates were observed for stromal cells (\(Mdn = 17.4\%\) in CVS vs. \(Mdn = 0.0\%\) at birth, \(Z = 8.0, p < 0.001\)), syncytiotrophoblasts (\(Mdn = 56.9\%\) in CVS vs. \(Mdn = 95.3\%\) at birth, \(Z = −8.0, p < 0.001\)), and trophoblasts (\(Mdn = 24.8\%\) in CVS vs. \(Mdn = 0.0\%\) at birth, \(Z = 8.0, p < 0.001\)) followed by endothelial cells (\(Mdn = 0.0\%\) in CVS vs. \(Mdn = 0.4\%\) at birth, \(Z = −6.1, p < 0.001\)), nRBC (\(Mdn = 0.0\%\) in CVS vs. \(Mdn = 3.2\%\) at birth, \(Z = −7.7, p < 0.001\)). This was based on 85 individuals from the ITU cohort for whom both CVS and placenta tissue at birth were available. Syncytiotrophoblasts were the most abundant estimated cell type in both CVS and term placenta tissue, but there was a strong median increase of 38.4% in this cell type from early-pregnancy to birth. The largest decrease from early-pregnancy to birth was in estimated trophoblasts from CVS to term placenta (median decrease of 24.8%), followed by estimated stromal cells (median decrease of 17.4%).

**Associations between reference-based estimated cell types and gestational age**

Finally, we wanted to see whether the estimated cell type proportions follow physiological changes over gestation. Higher GA at sampling was significantly related to lower estimated trophoblast proportions in CVS (\(r_t = −0.32, p < 0.001\)) and term placenta from the BET study (\(r_t = −0.42, p < 0.001\)), and to higher estimated syncytiotrophoblast proportions in CVS (\(r_t = 0.36, p < 0.001\)) and term placenta from the BET study (\(r_t = 0.37, p < 0.001\)). The effects were not significant, though in the same direction, for the other two data sets (term placenta from ITU and PREDO), where GA was more skewed towards higher gestational age. The relationship of estimated trophoblast and syncytiotrophoblast proportions with GA is shown in Fig. 7.

We observed no significant relationships with GA among the other estimated cell types.

Similar to Yuan et al. [17] we observed no significant sex-specific differences in estimated cell type proportions in any of the study samples.

**Discussion**

In this study, we examined a new DNAm-based reference which enables reference-based cell type estimation in placenta [17] in a large data set comprising over 1000 samples from three independent studies, with \(n = 746\) placental samples collected at birth, and \(n = 264\) during the first trimester of pregnancy. We investigated intra- as well as inter-individual differences in estimated cell type proportions. Furthermore, we compared the reference-based to a reference-free approach (namely, RefFreeEWAS) [31], regarding its potential to control for cell type proportions in DNAm studies of human placenta. We provide lists of CpGs from the EPIC
Fig. 6 Depicted are the mean and standard deviation of the reference-based estimated cell type’s proportion (raw estimates using the reference by Yuan et al. [17] and robust partial correlation algorithm) together with an illustration of the relative estimated cell type proportion in a), b), c) and d) individuals in CVS from ITU, in term placenta from ITU, c) in term placenta from PREDO and d) in term placenta from the BET study.
array which we found to be (1) non-variable in placental tissue (Supplementary Table S1), and (2) highly influenced by cell types (Supplementary Table S2).

Using a cross-validation model focusing on the prediction of the major variance in DNAm, as well as an investigation at single CpGs level, we confirmed the importance of cell type composition for variability in DNAm.

At the same time, the latter shows that it is a select subset of CpGs where the impact of cell type proportions on DNAm is especially important (Supplementary Table S2).

Both reference-free and reference-based cell type estimation methods can account for variability in DNAm. However, for the majority of data sets, the reference-based approach better predicted variability of DNAm.

Generally, reference-based cell type estimation allows for a more direct interpretation of cell type composition. This
was underscored by the fact that the overlap in CpGs with high amount of DNAm variability explained by estimated placental cell types was much more consistent among the different data sets when using reference-based cell types (26,092 CpGs) versus reference-free cell types (531 CpGs). Furthermore, genes mapping to these CpGs with high proportions of DNAm variability explained by estimated reference-based cell types were enriched for placenta-specific genes, while this was not the case when using the reference-free approach (see Fig. 4). A possible reason for this could be that the reference-free methods do not only depict cell types, but further unknown sources of variance, and as such it is difficult to interpret what the estimated reference-free ‘cell types’ actually reflect. This also becomes clear from Figs. 1 and 2, where we depict that reference-based estimated cell types are not highly correlated with a specific reference-free cell type component, but rather with child sex. This might also explain why in one of the term placenta data sets DNAm variability was better explained by reference-free compared to reference-based estimated cell types - probably not only cell types were covered by the estimated ‘cell types’ which contributed to DNA methylation in the complex tissue samples. This could suggest that even though reference-based cell type correction approaches outperform reference-free approaches in most settings, cohort-specific differences may affect the performance of these methods.

Overall, considering the performance of the reference-based cell type estimation, it may be advisable to use reference-based methods, such as from Yuan et al. [17] in future studies investigating DNAm in human placenta. Higher GA was associated with higher proportions of syncytiotrophoblasts and lower proportions of trophoblasts in the placenta samples collected at birth (Fig. 7). This finding was congruent with the changes in estimated cell type composition we observed from first trimester to birth placenta samples from the same individuals: trophoblast cells showed the largest decrease, syncytiotrophoblasts the largest increase. These differences in the estimated cell type proportions between early and late pregnancy are probably reflective of placental maturation process [42]. Trophoblasts give rise to further subpopulation of cells and syncytiotrophoblasts expand during pregnancy [5]. Yuan et al. [17] reported an increase in estimated syncytiotrophoblasts and endothelial cells and decrease in stromal cells from first trimester to term placenta samples, which is again concordant with our results despite their comparison of samples from different individuals, in contrast to our within-sample design in 85 individuals. Nevertheless, it should be mentioned that we cannot rule out that some of the differences in estimated cell type proportions may arise from differences in sampling and storage conditions of the CVS and the placental tissue.

Regarding child sex, Yuan et al. did not find any association with estimated cell composition [17]. We can confirm this result, as there was no evidence for sex-specific differences in reference-based estimated cell type composition. Additionally, the use of three independent studies (ITU, PREDO, BET) enabled us to investigate between-study differences in estimated cell type proportions at birth. We observed that cell type composition was rather consistent among samples within a study but different between studies. The larger variance in cell type proportions between studies (versus between individuals within a study) might reflect the different sampling schemes of placental tissue (see “Materials and methods”). The placenta is a highly complex organ, which makes the sampling procedure difficult and particularly prone to differences between studies [21, 43].

An important strength of our study is that we were able to investigate placental cell type composition in a large number of placentas from different independent studies. In addition to examining placental DNAm at birth, we included early-pregnancy placental CVS samples: in a subset of 85 individuals, longitudinal data on placental DNAm both in early pregnancy and at birth were available, giving us the rare chance to examine change over time within the same placentas. We also provide resources that can be used for the interpretation and design of DNAm studies in placenta, especially EWAS. However, there are also some limitations: we rely on bioinformatic indirect deconvolution, which also limits our investigation to the cell types included in the reference sample [17]. This was in turn limited by the availability of unique markers suitable for cell type selection using fluorescence-activated cell sorting, and dissection accuracy. Future tools based on single-nucleus DNA methylation analyses would undoubtedly improve cell type accuracy as well as diversity, thus improving usefulness for deconvolution in bulk tissue analyses. Furthermore, we only compared one reference-based deconvolution to one of several (semi-) reference-free approaches available [16]. Thus, our comparison of performance between methods is limited to these chosen approaches and is only an indication of the ability of the reference-based method to account for variability in DNAm compared to another often-used reference-free approach, but not generalizable to all reference-free methods. Additionally, we only used the first principal component of DNAm in the cross-validation procedure for model comparison, which is a reduction of dimensionality and improves interpretability, but at the same time can only capture part of the total variation in the data.

Overall, addressing cell type heterogeneity in studies of DNAm is important to avoid misinterpretation of results, to limit confounding and increase precision by distinguishing changes in cell type proportions from epigenetic changes due to other factors, such as for example environmental
exposures [44]. Apart from this, cell type composition is also an important factor to consider for understanding gene regulatory mechanisms in human tissues [45] and tissue function overall. This study contributes to a more detailed understanding of the interrelation between DNAm and estimated cell type composition in human placenta and stands as a resource to help researchers design future DNAm studies of human placenta and interpret results of both existing and future studies.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00018-021-04091-3.

Acknowledgements We would like to thank all of the midwives, obstetricians, and other medical staff, laboratory and research personnel, and administrative staff working in hospitals, antenatal and child wellbeing clinics, municipalities, national registers, and other institutions, whose efforts have made this research possible. We thank the midwives, Dr. A. Gusaurova, Dr. F. Braun-Tavares and A. K. Hardt at the Department for Obstetrics, Charité for valuable assistance in recruiting study participants. We also thank L. Ehrlich at the Department for Obstetrics, Charité for her assistance in placental tissue preparation. The PREDO study would not have been possible without the dedicated contribution of the PREDO study group members: E Hamäläinen, E Kajantie, H Laivuori, PM Villa, A-K Pesonen, A Aitokallio-Tallberg, A-M Henry, VK Hiilesmaa, T Karipohja, R Meri, S Sainio, T Saiisto, S Suomalainen-Konig, V-M Ulander, T Vahtila (Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland), L Keski-Nisula, Maija-Riitta Orden (Kuopio University Hospital, Kuopio Finland), E Koistinen, T Walle, R Solja (Northern Karelia Central Hospital, Joensuu, Finland), M Kurkinen (Päijät-Häme Central Hospital, Lahti, Finland), P. Taipale, P Staven (Isoalmpi Hospital, Isoalmpi, Finland), J Uotila (Tampere University Hospital, Tampere, Finland). The ITU study would not have been possible without the dedicated contribution of the staff at the Helsinki and Uusimaa Hospital District Feto-maternal Medical Center and delivery hospitals. We further thank S. Sauer, M. Ködel, M. Rex-Haffner and A. Tontsch for their technical support. We wish to express our deepest gratitude to all women and children who participated in the studies. Furthermore, we would like to thank Mark de Rooij for his support as regards the use of the R package xvalglms and enabling further functionalities in this package.

Author contributions DC, EB, KR and LD contributed to the study conception. Funding was acquired by SE, TB, JL, ML-P, KR, EB. Data collection and material preparation were performed by CC, ML-P, JL, TK, HL, SS, PMV, SS-K, RCR, AP, WH, JGE, EK, SE, TB and KR. Analyses were performed by LD and DC. The first draft of the manuscript was written by LD and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. The ITU study has been funded by the Academy of Finland (Award numbers: 1284859, 12848591, 312670 and 1324596) and the Finnish Diabetes Foundation. The PREDO Study has been funded by the Academy of Finland (JL: 311617 and 269925, KR: 1312670 ja 128789 1287891), EraNet Neuron, EVO (a special state subsidy for health science research), University of Helsinki Research Funds, the Signe and Ane Gyllenberg foundation, the Emil Aaltonen Foundation, the Finnish Medical Foundation, the Jane and Aatos Erkko Foundation, the Novo Nordisk Foundation, the Päiviikki and Sakari Sohliberg Foundation, Juho Vainio foundation, Yrjö Jahnsson foundation, The Finnish Society of Sciences and Letters, Jalmari and Rauha Ahokas foundation, Sigrid Juelius Foundation granted to members of the Predo study board. ML-P receives funding from the Academy of Finland, University of Helsinki Funds. AP and TB disclose receipt of financial support for the research, authorship, and/or publication of this article, supported by DFG (BR2925/3-1,-2,-3 and PL241/8-2,-3). EK reports support from Academy of Finland, Foundation for Pediatric Research, Sigrid Juelius Foundation and Novo Nordisk Foundation.

Availability of data and materials Due to the sensitive nature of the patient data used in the current study and consent, the data sets are not and cannot be made publicly available for data protection reasons.

Code availability R Code for the main analyses is provided here: https://doi.org/10.5281/zenodo.5713621.

Declarations

Conflict of interest EB is the coinventor of FKBP5: a novel target for antidepressant therapy, European Patent no. EP 1687443 B1, and receives a research grant from Böhringer Ingelheim for a collaboration on functional investigations of FKBP5. Otherwise, the authors declare that they have no competing interests.

Ethics approval and consent to participate/publish The ITU research protocol has been approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (approval date: 06.01.2015, reference number: 269/13/03/00/09). The PREDO study protocol was approved by the Ethics Committee of Obstetrics and Gynecology and Women, Children and Psychiatry of the Helsinki and Uusimaa Hospital District and by the participating hospitals. The BET study was approved by the Ethics Committee of the Charité-Universitätsmedizin, Berlin, Germany (EA2-149-07). In all studies, participants signed a written informed consent form.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Barker DJP (1995) Intrauterine programming of adult disease. Mol Med Today 1(9):418–423. https://doi.org/10.1016/s1357-4310(95)90793-9
2. Barker DJ (2007) The origins of the developmental origins theory. J Intern Med 261(5):412–417. https://doi.org/10.1111/j.1365-2796.2007.01809.x
3. Wadhwa PD, Buss C, Entrench S, Swanston JM (2009) Developmental origins of health and disease: brief history of the approach

Springer
and current focus on epigenetic mechanisms. Semin Reprod Med 27(5):358–368. https://doi.org/10.1055/s-0029-1237424

4. Lester BM, Marsit CJ (2018) Epigenetic mechanisms in the placenta related to infant neurodevelopment. Epigenomics 10(3):321–333. https://doi.org/10.2217/epi-2016-0171

5. Burton GJ, Fowden AL (2015) The placenta: a multifaceted, transient organ. Philos Trans R Soc Lond B Biol Sci 370(1663):20140066. https://doi.org/10.1098/rstb.2014.0066

6. Griffiths SK, Campbell JP (2015) Placental structure, function and drug transfer. Contin Educ Anaesth Crit Care Pain 15(2):84–89. https://doi.org/10.1093/bjaeeaccp/mku013

7. Marsit CJ (2016) Placental epigenetics in children’s environmental health. Semin Reprod Med 34(1):36–41. https://doi.org/10.1055/s-0035-1570028

8. Nelissen EC, van Montfoort AP, Dumoulin JC, Evers JL (2011) Epigenetics and the placenta. Hum Reprod Update 17(3):397–417. https://doi.org/10.1093/humupd/dmq052

9. Januar V, Desoye G, Novakovic B, Cvitic S, Saffery R (2015) Epigenetic regulation of human placental function and pregnancy outcome: considerations for causal inference. Am J Obstet Gynecol 213(4 Suppl):S182–S196. https://doi.org/10.1016/j.ajog.2015.07.011

10. Teschendorff AE, Relton CL (2018) Statistical and integrative system-level analysis of DNA methylation data. Nat Rev Genet 19(3):129. https://doi.org/10.1038/nrg.2017.86

11. Jaffe AE, Irizarry RA (2014) Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol 15(2):1–9. https://doi.org/10.1186/gb-2014-15-2-c31

12. Titus AJ, Gallimore RM, Salas LA, Christensen BC (2017) Cell-type deconvolution from DNA methylation: a review of recent applications. Hum Mol Genet 26(R2):R216–R224. https://doi.org/10.1093/hmg/ddx275

13. Houserman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT (2012) DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinform 13:86. https://doi.org/10.1186/1471-2105-13-86

14. Houserman EA, Molitor J, Marsit CJ (2014) Reference-free cell mixture adjustments in analysis of DNA methylation data. Bioinformatics 30(10):1431–1439. https://doi.org/10.1093/bioinformatics/btu029

15. Zou J, Lippert C, Heckerman D, Aryee M, Listgartten J (2014) Epigenome-wide association studies without the need for cell-type composition. Nat Methods 11(3):309–311. https://doi.org/10.1038/nmeth.2815

16. Teschendorff AE, Zheng SC (2017) Cell-type deconvolution in epigenome-wide association studies: a review and recommendations. Epigenomics 9(5):757–768. https://doi.org/10.2217/epi-2016-0153

17. Yuan V, Hui D, Yin Y, Penaherrera MS, Beristain AG, Robinson WP (2021) Cell-specific characterization of the placental methylome. BMC Genom 22(1):1–20. https://doi.org/10.1186/s12864-020-07186-6

18. Girchenko P, Lahiti M, Tuovinen S, Savolainen K, Lahiti J, Binder EB, Reynolds RM, Entringer S, Buss C, Wadhwa PD, Hamalainen E, Kajantie E, Pesonen AK, Villa PM, Laivuori H, Raikkonen K (2017) Cohort Profile: Prediction and prevention of preclampsia and intrauterine growth restriction (PREDO) study. Int J Epidemiol 46(5):1380–1381g. https://doi.org/10.1093/ije/dyw154

19. Braun F, Hardt AK, Ehrlich L, Sloboda DM, Challis JRG, Plagemann A, Heinrich W, Braun T (2018) Sex-specific and lasting effects of a single course of antenatal betamethasone treatment on human placental 1beta-HSD2. Placenta 69:9–19. https://doi.org/10.1016/j.placenta.2018.07.007

20. Braun T, Husar A, Challis JR, Dudenhausen JW, Henrich W, Plagemann A, Sloboda DM (2013) Growth restricting effects of a single course of antenatal betamethasone treatment and the role of human placental lactogen. Placenta 34(5):407–415. https://doi.org/10.1016/j.placenta.2013.02.002

21. Mayhew TM (2008) Taking tissue samples from the placenta: an illustration of principles and strategies. Placenta 29(1):1–14. https://doi.org/10.1016/j.placenta.2007.05.010

22. Maksimovic J, Phipson B, Oshlack A (2017) A cross-package Bioconductor workflow for analysing methylation array data. F1000Research 5:1–52. https://doi.org/10.12688/f1000research.8839.3

23. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA (2014) Minfi: a flexible and comprehensive Bioconductor package for the analysis of Illumina DNA methylation microarrays. Bioinformatics 30(10):1363–1369. https://doi.org/10.1093/bioinformatics/btu049

24. Touleimat N, Tost J (2012) Complete pipeline for Illumina Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimations. Epigenomics 4(3):325–341. https://doi.org/10.2217/epi.12.21

25. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S (2013) A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 29(2):189–196. https://doi.org/10.1093/bioinformatics/bts080

26. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD (2012) The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6):882–883. https://doi.org/10.1093/bioinformatics/bts034

27. Barfield RT, Almli LM, Kilaru V, Smith AK, Mercer KB, Duncan R, Kengel T, Mehta D, Binder EB, Epstein MP, Ressler KJ, Conneely KN (2014) Accounting for population stratification in DNA methylation studies. Genet Epidemiol 38(3):231–241. https://doi.org/10.1002/gepi.21789

28. Dieckmann L, Lahti-Pulkkinnen M, Kvist T, Lahiti J, DeWitt PE, Crueceau C, Laivuori H, Sammallahti S, Villa PM, Suomalainen-Konig S, Eriksson JG, Kajantie E, Raikkonen K, Binder EB, Czmara D (2021) Characteristics of epigenetic aging across gestational and perinatal tissues. Clin Epigenet 13(1):97. https://doi.org/10.1186/s13148-021-01080-y

29. Czmara D, Dieckmann L, Kraemer S, Rancourt RC, Sammallahti S, Kajantie E, Laivuori H, Eriksson JG, Raikkonen K, Henrich W, Plagemann A, Binder EB, Braun T, Entgringer S (2021) Betamethasone administration during pregnancy is associated with placental epigenetic changes with implications for inflammation. Clin Epigenet 13(1):165. https://doi.org/10.1186/s13148-021-01153-y

30. Teschendorff AE, Breeze CE, Zheng SC, Beck S (2017) A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. BMC Bioinform 18(1):105. https://doi.org/10.1186/s12859-017-1511-5

31. Houserman EA, Kile ML, Christiani DC, Ince TA, Kelsey KT, Marsit CJ (2016) Reference-free deconvolution of DNA methylation data and mediation by cell composition effects. BMC Bioinform 17:259. https://doi.org/10.1186/s12859-016-1140-4

32. R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria

33. Edgar RD, Jones MJ, Robinson WP, Kobor MS (2017) An empirically driven data reduction method on the human 450K methylation array to remove tissue specific non-variable CpGs. Clin Epigenet 9:11. https://doi.org/10.1186/s13147-017-0320-z
Reliability of a novel approach for reference-based cell type estimation in human placental…

34. Rooij Md, Weeda W (2020) Cross-validation: a method every psychologist should know. Adv Methods Pract Psychol Sci 3(2):248–263. https://doi.org/10.1177/2515245919898466
35. Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, irizarry RA (2012) Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol 41(1):200–209. https://doi.org/10.1093/ije/dyr238
36. Jain A, Tuteja G (2019) TissueEnrich: tissue-specific gene enrichment analysis. Bioinformatics 35(11):1966–1967. https://doi.org/10.1093/bioinformatics/ght790
37. Jain A, Tuteja G (2021) PlacentaCellEnrich: a tool to characterize gene sets using placenta cell-specific gene enrichment analysis. Placenta 103:164–171. https://doi.org/10.1016/j.placenta.2020.10.029
38. Vento-Tormo R, Efremova M, Botting RA, Turco MY, Vento-Tormo M, Meyer KB, Park JE, Stephenson E, Polanski K, Gonzales A, Gardner L, Holmqvist S, Henriksson J, Zou A, Shock AM, Millar B, Innes B, Wood L, Wilbrey-Clark A, Payne RP, Jørgensen MA, Lisgo S, Filby A, Rowitch DH, Bulmer JN, Wright GJ, Stubington MT, Hinniha M, Moffett A, Teichmann SA (2018) Single-cell reconstruction of the early maternal-fetal interface in humans. Nature 563(7731):347–353. https://doi.org/10.1038/s41586-018-0698-6
39. Bathke AC, Harrar SW, Madden LV (2008) How to compare small multivariate samples using nonparametric tests. Comput Stat Data Anal 52(11):4951–4965. https://doi.org/10.1016/j.csda.2008.04.006

Authors and Affiliations

Linda Dieckmann1,2 · Cristina Cruceanu1 · Marius Lahti-Pulkkinen3,4,5 · Jari Lahti3 · Tuomas Kvist3 · Hannele Laivuori6,7,8 · Sara Sammallahti3,4,9,10 · Pia M. Villa8,11,12 · Sanna Suomalainen-König11 · Eero Kajantie4,9,10,21 · Sonja Entringer21,22 · Thorsten Braun14 · Katri Räikkönen3 · Elisabeth B. Binder1,23 · Cristiana Cruceanu1 · Marius Lahti-Pulkkinen3,4,5 · Jari Lahti3 · Tuomas Kvist3 · Hannele Laivuori6,7,8 · Sara Sammallahti3,4,9,10 · Pia M. Villa8,11,12 · Sanna Suomalainen-König11 · Eero Kajantie4,9,10,21 · Sonja Entringer21,22 · Thorsten Braun14 · Katri Räikkönen3 · Elisabeth B. Binder1,23 · Darina Czamara1

1 Department of Translational Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
2 International Max Planck Research School for Translational Psychiatry, Munich, Germany
3 Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland
4 Finnish Institute for Health and Welfare, Helsinki, Finland
5 Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
6 Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Human Genetics, Helsinki, Finland
7 Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
8 Department of Obstetrics and Gynecology, Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health, Tampere University Hospital and University of Tampere, Tampere, Finland
9 Children’s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
10 Department of Child and Adolescent Psychiatry, Erasmus MC, Sophia Children’s Hospital, Rotterdam, The Netherlands
11 Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
12 Hyvinkää Hospital, Helsinki and Uusimaa Hospital District, Hyvinkää, Finland
13 Department of Experimental Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
14 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
15 Department of General Practice, University of Helsinki, Helsinki, Finland
16 Folkhälsan Research Center, Helsinki, Finland
17 Department of Obstetrics and Gynaecology and Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
18 Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
19 Department of Translational Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
20 Department of Translational Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
21 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
22 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
23 Department of Translational Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
24 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
25 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
26 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
27 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
28 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
29 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
30 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
31 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
32 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
33 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
34 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
35 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
36 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
37 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
38 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
39 Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
40. Burchett WW, Ellis AR, Harrar SW, Bathke AC (2017) Non-parametric inference for multivariate data: the R package nmpv. J Stat Softw. https://doi.org/10.18637/jss.v076.i04
41. Liu Y, Fan X, Wang R, Lu X, Dang YL, Wang H, Lin HY, Zhu C, Ge H, Cross JC, Wang H (2018) Single-cell RNA-seq reveals the diversity of trophoblast subtypes and patterns of differentiation in the human placenta. Cell Res 28(8):819–832. https://doi.org/10.1038/s41422-018-0066-y
42. Turco MY, Moffett A (2019) Development of the human placenta. Development. https://doi.org/10.1242/dev.136428
43. Burton GJ, Sebire NJ, Myatt LS, Tannetta D, Wang YL, Sadovsky Y, Staff AC. Redman CW (2014) Optimising sample collection for placental research. Placenta 35(1):9–22. https://doi.org/10.1016/j.placenta.2013.11.005
44. Campbell KA, Colacino JA, Park SK, Bakulski KM (2020) Cell types in environmental epigenetic studies: biological and epide- miological frameworks. Curr Environ Health Rep 7(3):185–197. https://doi.org/10.1007/s40572-020-00287-0
45. GTEx Consortium (2019) The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369(6509):1318–1330. https://doi.org/10.1101/787903

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
19 Faculty of Medicine, PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

20 Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

21 Institute of Medical Psychology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin,

22 Humboldt-Universität Zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany

23 Department of Pediatrics, Development, Health, and Disease Research Program, University of California, Irvine, CA, USA

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA